For this purpose, upon validation of a TP53 next generation sequencing screening (performed on a total of 80 B-CLL patients), we selected 5 patients with p53 wild-type and 5 patients characterized by mutations potentially affecting p53 functionality, as predicted by web mutation pathogenicity prediction tools and protein structural bioinformatic analysis (Table 1 and Supplementary Figure 1). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.